Journal article
Safety and immunogenicity of novel adenovirus type 26– and modified vaccinia Ankara–vectored ebola Vaccines
In this phase 1 study of healthy volunteers, immunization with Ad26.ZEBOV or MVA-BN-Filo did not result in any vaccine-related serious adverse events. An immune response was observed after primary immunization with Ad26.ZEBOV; boosting by MVA-BN-Filo resulted in sustained elevation of specific immunity. These vaccines are being further assessed in phase 2 and 3 studies.
Authors
Languages
- English
Publication year
2016
Journal
JAMA
Volume
15
Type
Journal article
Categories
- Vaccines & delivery devices
Diseases
- Ebola
Tags
- New vaccine introduction